February 13, 2017
Egalet Corp. investors filed a second securities class complaint Friday over the U.S. Food and Drug Administration's recent approval of an opioid painkiller, telling a Pennsylvania federal court that the company made misleading statements about the drug's likelihood of earning a label denoting the painkiller's ability to deter abuse.